Former Catalan Health Minister Josep Maria Argimon testified in court regarding the administration of COVID-19 vaccines to National Police and Civil Guard officers stationed in Catalonia. Argimon, who served as the director of the Catalan Health Service and Secretary of Public Health during the pandemic, maintained that the decision to restrict the AstraZeneca vaccine to the 60-to-65 age bracket was based on directives from the Interterritorial Council of Health.

The Rationale Behind Vaccination Restrictions

During his testimony, Argimon stated that the age-based limitations placed on the AstraZeneca vaccine were neither an ethical nor an epidemiological conflict. According to his account, the policy was designed to prioritize the most vulnerable segments of the population. Argimon emphasized that these restrictions were applied consistently, regardless of whether individuals were classified as essential workers.

The legal proceedings examine the distribution protocols for security forces. While the defense of the age-restricted rollout centered on alignment with the Interterritorial Council’s broader strategy, Argimon clarified that his personal position regarding the personnel in question differed from the eventual implementation.

Logistics and Internal Communication

Despite the constraints imposed by the national health body, Argimon testified that he favored continuing the vaccination process for all police officers. He noted that the logistical framework required to execute a broader vaccination plan was already in place at the time.

Argimon stated that he communicated his preference to then-Minister of Health Alba Vergés. The testimony highlights the tension between local administrative readiness and the national health directives that dictated the cadence and eligibility criteria for vaccine distribution across Spanish regions.

Context of the Vaccination Campaign

The trial centers on the complexities of vaccine rollout strategies. Health authorities across Europe frequently adjusted their guidelines as new safety data emerged, often leading to discrepancies between regional expectations and national mandates.

Argimon’s testimony serves as a key component in understanding how these decisions were brokered and why specific groups—such as law enforcement officers—experienced delays or changes in their anticipated vaccination schedules.

Next Steps in the Legal Proceedings

The court is expected to continue hearing testimony from former health officials and administrative staff involved in the management of the COVID-19 immunization program. These proceedings remain a significant point of review for the judicial system as it evaluates the transparency and fairness of health policies implemented during the public health crisis.

Updates on the trial’s progress will be provided as additional testimony is recorded and official court documentation becomes available. Readers can follow further developments on this case through official judicial bulletins and verified reporting channels.